Academia and industry: allocating credit for discovery and development of new therapies.
作者信息
Flier Jeffrey S
出版信息
J Clin Invest. 2019 May 20;129(6):2172-2174. doi: 10.1172/JCI129122.
Abstract
摘要
相似文献
1
Academia and industry: allocating credit for discovery and development of new therapies.学术界与产业界：为新疗法的发现与开发分配功劳。
J Clin Invest. 2019 May 20;129(6):2172-2174. doi: 10.1172/JCI129122.
2
David Haslam. Interview by Asher Mullard.大卫·哈斯拉姆。由亚瑟·穆拉德进行的访谈。
Nat Rev Drug Discov. 2013 Jul;12(7):500. doi: 10.1038/nrd4053. Epub 2013 Jun 14.
3
How to develop therapeutic and translational research collaborations with industry.如何与业界开展治疗和转化研究合作。
Mol Biol Cell. 2019 Oct 15;30(22):2741-2743. doi: 10.1091/mbc.E19-05-0261.
4
Drug discovery for the developing world: progress at the Novartis Institute for Tropical Diseases.面向发展中世界的药物研发：诺华热带病研究所的进展
Nat Rev Drug Discov. 2015 Jun;14(6):442-4. doi: 10.1038/nrd4001-c1.
5
Academic-industrial partnerships in drug discovery in the age of genomics.基因组学时代药物研发中的产学研合作。
Trends Biotechnol. 2015 Jun;33(6):320-2. doi: 10.1016/j.tibtech.2015.02.009.
6
The changing roles of industry and academia.产业界和学术界角色的转变。
J Invest Dermatol. 2012 Mar;132(3 Pt 2):1033-6. doi: 10.1038/jid.2011.368.
7
Drug industry in "depression".制药行业陷入“低迷”。
Med Sci Monit. 2005 Jan;11(1):SR1-4.
8
Hopes build that new infrastructure can aid drug discovery.人们越发希望新的基础设施能够助力药物研发。
Nat Med. 2011 Oct 11;17(10):1174-5. doi: 10.1038/nm1011-1174b.
9
Pacific sunrise.太平洋日出。
Nature. 2006 Feb 23;439(7079):1026-7. doi: 10.1038/nj7079-1026a.
10
Florida welcomes Scripps as critics predict big-money flop.尽管批评人士预测会惨败，但佛罗里达州仍欢迎斯克里普斯（入驻）。
Nature. 2003 Nov 6;426(6962):4. doi: 10.1038/426004b.
引用本文的文献
1
How to respond when biomedical science and global health is under existential threat.
Nat Rev Immunol. 2025 May;25(5):313-314. doi: 10.1038/s41577-025-01166-1.
2
Drug repurposing in amyotrophic lateral sclerosis (ALS).肌萎缩侧索硬化症（ALS）中的药物重新利用。
Expert Opin Drug Discov. 2025 Apr;20(4):447-464. doi: 10.1080/17460441.2025.2474661. Epub 2025 Mar 7.
3
Funding multinational investigator-initiated clinical studies in Europe: why and how?在欧洲资助跨国研究者发起的临床研究：为什么以及如何？
Trials. 2024 Oct 17;25(1):689. doi: 10.1186/s13063-024-08548-1.
4
The fate of drug discovery in academia; dumping in the publication landfill?学术界药物研发的命运；被丢弃在出版物的垃圾填埋场？
Oncotarget. 2024 Jan 24;15:31-34. doi: 10.18632/oncotarget.28552.
5
Demystifying Supervised Learning in Healthcare 4.0: A New Reality of Transforming Diagnostic Medicine.揭开医疗保健4.0中监督学习的神秘面纱：变革诊断医学的新现实。
Diagnostics (Basel). 2022 Oct 20;12(10):2549. doi: 10.3390/diagnostics12102549.
6
An urgent call to raise the bar in oncology.呼吁提高肿瘤学水平。
Br J Cancer. 2021 Nov;125(11):1477-1485. doi: 10.1038/s41416-021-01495-7. Epub 2021 Aug 16.
7
Transformative dynamism in pharmaceutical and biomedical research: Complexity of integration of innovative R & D hubs.制药与生物医学研究中的变革性活力：创新研发中心整合的复杂性
Bioimpacts. 2021;11(3):227-233. doi: 10.34172/bi.2021.29. Epub 2021 Feb 24.
8
Public research funding and pharmaceutical prices: do Americans pay twice for drugs?公共研究经费与药品价格：美国人是否要为药品支付双倍费用？
F1000Res. 2020 Jul 15;9:707. doi: 10.12688/f1000research.24934.1. eCollection 2020.
9
The Resurrection of Phenotypic Drug Discovery.表型药物发现的复兴
ACS Med Chem Lett. 2020 Mar 6;11(10):1820-1828. doi: 10.1021/acsmedchemlett.0c00006. eCollection 2020 Oct 8.
本文引用的文献
1
Fundamental science behind today's important medicines.当今重要药物背后的基础科学。
Sci Transl Med. 2018 Apr 25;10(438). doi: 10.1126/scitranslmed.aaq1787.
2
Pricing in the Market for Anticancer Drugs.抗癌药物市场的定价
J Econ Perspect. 2015;29(1):139-62. doi: 10.1257/jep.29.1.139.
3
Irreproducibility of published bioscience research: Diagnosis, pathogenesis and therapy.已发表生物科学研究的不可重复性：诊断、发病机制与治疗
Mol Metab. 2016 Nov 21;6(1):2-9. doi: 10.1016/j.molmet.2016.11.006. eCollection 2017 Jan.
4
Innovation in the pharmaceutical industry: New estimates of R&D costs.制药行业的创新：研发成本的新估计
J Health Econ. 2016 May;47:20-33. doi: 10.1016/j.jhealeco.2016.01.012. Epub 2016 Feb 12.
5
Reproducibility in science: improving the standard for basic and preclinical research.科学可重复性：提高基础和临床前研究的标准。
Circ Res. 2015 Jan 2;116(1):116-26. doi: 10.1161/CIRCRESAHA.114.303819.
6
Why most published research findings are false.为何大多数已发表的研究结果是错误的。
PLoS Med. 2005 Aug;2(8):e124. doi: 10.1371/journal.pmed.0020124. Epub 2005 Aug 30.
7
Augmenting reference pricing of pharmaceuticals in New Zealand with strategic cross-product agreements.
Pharmacoeconomics. 2001;19(4):365-77. doi: 10.2165/00019053-200119040-00004.
Zotero 插件